Case to be Presented at 2022 Advanced Shoulder Arthroplasty Meeting on Jan. 21
Stryker, one of the world’s leading medical technology companies, announced today that its new Tornier Perform® Patient-Matched Primary Reversed Glenoid (Patient-Matched Glenoid) was used in a surgical procedure for the first time. The case was completed Jan. 13 by Jay Keener, M.D., in St. Louis and will be highlighted in a presentation at the 2022 Advanced Shoulder Arthroplasty (ASAP) Meeting on Jan. 21 in Snowbird, Utah.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220120005355/en/
Stryker's Tornier Perform® Patient-Matched Glenoid is the first surgeon-driven, primary patient-specific implant available in shoulder arthroplasty. (Photo: Business Wire)
The limited-market release Patient-Matched Glenoid is the first surgeon-driven, primary patient-specific implant available in shoulder arthroplasty. Taking into account the surgeon’s surgical preference and patient need, it is a patient-matched implant that is planned on Stryker’s Blueprint® 3D Planning Software.
“The Patient-Matched Glenoid puts surgeons in the driver’s seat to contour the implant to the face of the native glenoid that is unique to each patient’s anatomy,” said Dr. George S. Athwal, one of the designers of the implant system. “The Patient-Matched Glenoid system increases efficiency in the OR, requiring fewer surgical steps and no glenoid bone reaming.”
To generate the Patient-Matched Glenoid, the surgeon uses Blueprint Software to virtually position and execute the creation of a patient-matched implant. Once completed in Blueprint, an order is generated to manufacture the glenoid baseplate and patient-specific instrumentation (PSI). The surgeon will receive the sterile devices and execute the implantation of the baseplate using a ream-free, bone-preserving technique.
“Stryker’s relentless pursuit of innovation is exemplified in the Patient-Matched Glenoid, a strong addition to our upper extremities portfolio,” said Tim Lanier, Vice President & General Manager, Upper Extremities at Stryker. “It will give our customers autonomy that is not available anywhere else in the market.”
To learn more about the presentation discussing the Patient-Matched Glenoid at ASAP on Jan. 21, visit https://asapmeeting.org.
About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.
Follow Stryker Upper Extremities on LinkedIn and Stryker’s Trauma & Extremities division on Twitter.
A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.
Content ID: AP-015732A
Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Blueprint, Perform, Stryker, Tornier. All other trademarks are trademarks of their respective owners or holders.
Copyright © 2022 Stryker
View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005355/en/
Contacts
Andrea Sampson, Sampson Public Relations Group
asampson@sampsonprgroup.com
562.304.0301
